PPH
VanEck Pharmaceutical ETF
Price Chart
Latest Quote
$110.04
+0.15 (+0.14%)
Current Price
| Previous Close | $109.89 |
| Open | $109.94 |
| Day High | $111.47 |
| Day Low | $109.59 |
| Volume | 497,456 |
Fund Information
| Quarterly Dividend / Yield | N/A / 1.97% |
| Shares Outstanding | 11.55M |
| Net Assets | $879.46M |
| Expense Ratio | 0.36% |
| Category | Health |
| Fund Family | VanEck |
| Net Asset Value | $110.02 |
| Premium/Discount | 0.02% |
| Quarterly Dividend Yield | 1.97% |
| P/E Ratio | 23.85 |
| Exchange | NGM |
📊 ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $108.04 |
| SMA50 | $104.92 |
| SMA200 | $101.56 |
| RSI | 53.51 |
| ATR | 1.9322 |
| Rel Volume | 1.59 |
Performance History
| Week | +1.14% |
| Month | +5.31% |
| Quarter | +7.65% |
| 6 Months | +4.54% |
| YTD | +7.58% |
| Year | +27.89% |
| 3 Years | +51.75% |
| 5 Years | +65.01% |
| 10 Years | +119.57% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $110.04 | 497,500 |
| 2026-07-16 | $109.88 | 88,200 |
| 2026-07-15 | $107.52 | 75,400 |
| 2026-07-14 | $106.78 | 96,200 |
| 2026-07-13 | $108.78 | 125,900 |
| 2026-07-10 | $108.80 | 263,700 |
| 2026-07-09 | $109.63 | 142,700 |
| 2026-07-08 | $110.33 | 347,000 |
| 2026-07-07 | $111.60 | 558,700 |
| 2026-07-06 | $109.96 | 322,900 |
| 2026-07-02 | $111.39 | 469,400 |
| 2026-07-01 | $107.95 | 219,400 |
| 2026-06-30 | $108.72 | 259,600 |
| 2026-06-29 | $109.82 | 876,700 |
| 2026-06-26 | $108.81 | 207,800 |
| 2026-06-25 | $106.20 | 381,400 |
| 2026-06-24 | $105.13 | 143,600 |
| 2026-06-23 | $104.72 | 122,800 |
| 2026-06-22 | $102.88 | 221,100 |
| 2026-06-18 | $101.94 | 825,400 |
About VanEck Pharmaceutical ETF
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
📰 Latest News
4 ETF Winners of June Likely to Gain in July
Zacks • 2026-07-08T14:00:00Z
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
Zacks • 2026-06-10T16:00:00Z
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
Zacks • 2026-06-05T10:20:02Z
Even If Eli Lilly Stock Continues to Shine, Stay Away from This Pharmaceutical ETF
Barchart • 2026-06-02T19:02:50Z
Sickly Healthcare Stocks Are Perking Up. For Contrarian Investors, Buying Now Could Be Just the Remedy to Protect Your Portfolio.
Barchart • 2026-05-24T12:30:02Z
AbbVie Stock: Is Wall Street Bullish or Bearish?
Barchart • 2026-05-11T11:54:54Z
Healthcare ETFs in Spotlight Amid Eli Lily's $2.8B AI Drug Move
Zacks • 2026-03-30T14:40:00Z
PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026
24/7 Wall St. • 2026-03-28T11:15:33Z
FDA Clears NVO's Higher Dose of Wegovy: Diversify With These Health ETFs
Zacks • 2026-03-23T15:27:00Z
Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook
Zacks • 2026-02-04T14:30:00Z
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.